MDRX
Veradigm Inc. Healthcare - Health Information Services Investor Relations →
Veradigm Inc. (MDRX) closed at $4.80 as of 2026-06-19, trading 48.5% below its 200-week moving average of $9.32. This places MDRX in the extreme value zone. The stock moved further from the line this week, up from -48.9% last week. The 14-week RSI sits at 49, indicating neutral momentum.
Over the past 14 weeks, down-weeks have had more trading volume than up-weeks (0.41 buyers-vs-sellers ratio). That means when people are active, they're more often selling than buying. Sellers are still more in control than buyers.
Over the past 1355 weeks of data, MDRX has crossed below its 200-week moving average 16 times. On average, these episodes lasted 49 weeks. The average one-year return after crossing below was -9.9%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $517 million, MDRX is a small-cap stock. The company generates a free cash flow yield of 3.0%. Return on equity stands at -31.0%. The stock trades at 0.6x book value.
Over the past 26 years, a hypothetical investment of $100 in MDRX would have grown to $49, compared to $829 for the S&P 500. MDRX has returned -2.7% annualized vs 8.5% for the index, underperforming the broader market over this period.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: MDRX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MDRX Crosses Below the Line?
Across 16 historical episodes, buying MDRX when it crossed below its 200-week moving average produced an average return of -8.0% after 12 months (median -7.0%), compared to +6.8% for the S&P 500 over the same periods. 31% of those episodes were profitable after one year. After 24 months, the average return was +9.2% vs +17.8% for the index.
Each line shows $100 invested at the moment MDRX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Dislocation Scores Experimental
Each score measures deviation from MDRX's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
MDRX has crossed below its 200-week MA 16 times with an average 1-year return of +-9.9% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 2000 | Feb 2004 | 189 | 87.4% | -72.9% | -55.5% |
| Nov 2007 | Nov 2007 | 1 | 0.2% | -11.8% | -30.8% |
| Jan 2008 | Dec 2008 | 48 | 70.9% | +43.1% | -26.3% |
| Apr 2012 | Jan 2014 | 90 | 45.7% | +33.9% | -53.4% |
| Apr 2014 | Jun 2014 | 11 | 9.3% | -22.2% | -69.6% |
| Jul 2014 | Jul 2014 | 1 | 0.9% | -15.9% | -69.5% |
| Jul 2014 | Jul 2015 | 52 | 25.6% | -6.5% | -69.0% |
| Aug 2015 | Oct 2015 | 10 | 10.6% | -6.5% | -65.9% |
| Feb 2016 | Apr 2016 | 9 | 10.4% | -7.8% | -62.0% |
| Apr 2016 | Jul 2016 | 10 | 10.9% | -10.7% | -64.2% |
| Jul 2016 | Jul 2016 | 1 | 0.2% | -12.4% | -65.3% |
| Aug 2016 | Sep 2017 | 57 | 26.6% | -3.7% | -63.5% |
| Oct 2017 | Nov 2017 | 3 | 6.8% | -24.6% | -62.9% |
| Mar 2018 | Jul 2018 | 20 | 11.5% | -19.3% | -63.6% |
| Oct 2018 | Nov 2020 | 106 | 53.5% | -11.8% | -61.4% |
| Mar 2023 | Ongoing | 171+ | 70.1% | Ongoing | -63.4% |
| Average | 49 | — | +-9.9% | — |
Frequently Asked Questions
Is MDRX below its 200-week moving average?
Yes. As of 2026-06-19, Veradigm Inc. (MDRX) is trading 48.5% below its 200-week moving average of $9.32. The current price is $4.80.
What is MDRX's 200-week moving average price?
Veradigm Inc.'s 200-week moving average is $9.32 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when MDRX drops below its 200-week moving average?
MDRX has crossed below its 200-week moving average 16 times in our data. The average one-year return after these crossings was -9.9%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 49 weeks on average.
Is MDRX a good value right now?
Here's what our data says about MDRX as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 49. Free cash flow yield is 3.0%. Return on equity is -31.0%. Price-to-book is 0.6x. This is not a buy or sell recommendation — always do your own research.
How does MDRX compare to the S&P 500?
Over the past 26 years, $100 invested in MDRX would have grown to $49, compared to $829 for the S&P 500. That's -2.7% annualized vs 8.5% for the index. MDRX has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19